Significant Ownership of Affinity Asset Advisors, LLC
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Affinity Asset Advisors, LLC focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Andrew Weinstein - Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer
- Manager location
- New York, NY
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Affinity Asset Advisors, LLC with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Affinity Asset Advisors, LLC
Significant Ownership of Affinity Asset Advisors, LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| IBIO | iBio, Inc. | Common Stock, par value $0.001 per share | 10% | $7,349,879 | +$2,290,759 | 5,068,882 | +45% | Affinity Asset Advisors, LLC | 30 Jun 2026 |
| VTYX | Ventyx Bioscience, Inc. | Common Stock, $0.0001 par value per share | 9% | $58,381,906 | +$21,744,625 | 6,465,041 | +59% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| STRO | Sutro Biopharma, Inc. | Common Stock, $0.001 par value per share | 8.8% | $8,444,817 | 748,382 | Affinity Asset Advisors, LLC | 22 Jan 2026 | ||
| KPTI | Karyopharm Therapeutics Inc. | Common Stock, $0.0001 par value per share | 8.6% | $12,870,974 | +$7,880,460 | 1,713,092 | +158% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| KPTI | Karyopharm Therapeutics Inc. | Common Stock, $0.0001 par value per share | 8.6% | $1,244,110 | 2,073,517 | Affinity Asset Advisors, LLC | 31 Mar 2026 | ||
| LXEO | Lexeo Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 8.4% | $30,704,600 | +$6,703,364 | 6,674,913 | +28% | Affinity Asset Advisors, LLC | 30 Jun 2026 |
| OVID | Ovid Therapeutics Inc. | Common Stock, par value $0.001 per share | 7.9% | $41,342,377 | -$1,342,494 | 15,143,728 | -3.1% | Affinity Asset Advisors, LLC | 30 Jun 2026 |
| FBRX | Forte Biosciences, Inc. | Common Stock, par value $0.001 per share | 7.3% | 1,011,890 | Affinity Asset Advisors, LLC | 31 Mar 2026 | |||
| HLXC | Helix Acquisition Corp. III | Class A ordinary shares, par value $0.0001 per share | 7% | $12,700,000 | 1,250,000 | Affinity Asset Advisors, LLC | 31 Mar 2026 | ||
| STRO | Sutro Biopharma, Inc. | Common stock, $0.001 par value per share | 6.5% | $26,642,467 | -$137,363,902 | 1,069,519 | -84% | Affinity Asset Advisors, LLC | 31 Mar 2026 |
| EQ | Equillium Inc. | Common Stock, par value $0.0001 per share | 6.5% | $12,915,000 | 4,100,000 | Affinity Asset Advisors, LLC | 30 Jun 2026 | ||
| NXTC | NextCure, Inc. | Common Stock, $0.001 par value per share | 6.4% | $597,479 | -$162,484 | 274,073 | -21% | Affinity Asset Advisors, LLC | 30 Jun 2026 |
| TRAX | First Tracks Biotherapeutics, Inc | Common Stock, par value $0.001 per share | 5.8% | $71,140,740 | 2,032,012 | Affinity Asset Advisors, LLC | 30 Jun 2026 | ||
| FBRX | Forte Biosciences, Inc. | Common Stock, par value $0.001 per share | 5.6% | $50,534,651 | +$13,696,039 | 1,145,391 | +37% | Affinity Asset Advisors, LLC | 30 Jun 2026 |
| AVTX | Avalo Therapeutics, Inc. | Common Stock, $0.001 par value per share | 5.5% | $55,709,000 | +$29,951,464 | 2,900,000 | +116% | Affinity Asset Advisors, LLC | 30 Jun 2026 |
| VRCA | Verrica Pharmaceuticals Inc. | Common Stock, $0.0001 par value per share | 5.5% | $7,346,762 | 884,172 | 0% | Affinity Asset Advisors, LLC | 22 Jan 2026 | |
| AMAN | Amanat Acquisition Corp. | Class A ordinary shares, par value $0.0001 per share | 5% | $3,798,750 | 375,000 | Affinity Asset Advisors, LLC | 30 Jun 2026 | ||
| INZY | Inozyme Pharma, Inc. | Common Stock, par value $0.0001 per share | 2.9% | $2,203,898 | 1,867,710 | Affinity Healthcare Fund, LP | 20 May 2025 |
Schedules 13D/G Reported by Affinity Asset Advisors, LLC:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.